Form 4: Supernus Pharmaceuticals Director Bethany Sensenig Acquires Stock Options and Restricted Stock Units

Director Bethany Sensenig reports acquisition of stock options and restricted stock units in Supernus Pharmaceuticals.

Summary

• On February 19, 2025, Bethany Sensenig, a director of Supernus Pharmaceuticals, acquired stock options and restricted stock units (RSUs).
• Sensenig acquired options to purchase 7,296 shares of common stock at an exercise price of $33.52, vesting on February 19, 2026, and expiring on February 19, 2035.
• Sensenig also acquired 4,475 restricted stock units, each representing the right to receive one share of Supernus common stock upon vesting on February 19, 2026.
• Following these transactions, Sensenig directly owns 7,296 stock options and 4,475 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of stock options and RSUs can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the stock options and RSUs in 2026 suggests a long-term incentive for the director to contribute to the company's success.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to align management's interests with those of shareholders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, SUPN